Item 2.02. Results of Operations and Financial Condition.
Marinus Pharmaceuticals, Inc. (the "Company") issued a press release on November
9, 2020 announcing its financial results for the quarter ended September 30,
2020 and providing a business update. A copy of the press release is being
furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
by reference to this Item 2.02.
The information furnished pursuant to this Item 2.02 shall not be deemed to be
"filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the
"Exchange Act") or otherwise subject to the liabilities of that section, nor
shall it be deemed to be incorporated by reference into any of the Company's
filings with the Securities and Exchange Commission under the Exchange Act or
the Securities Act of 1933, whether made before or after the date hereof,
regardless of any general incorporation language in such a filing, except as
expressly set forth by specific reference in such a filing. Except as required
by law, we undertake no duty or obligation to publicly update or revise the
information so furnished.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
99.1 Press Release, dated November 9, 2020, of Marinus Pharmaceuticals,
Inc.
104 The cover page from this Current Report on Form 8-K, formatted in
Inline XBRL
2
© Edgar Online, source Glimpses